Answer
The mean bioavailability of teclistamab after subcutaneous administration is 72%.
Sources for this answer
- TECVAYLI 90mg/ml solution for injectionJanssen-Cilag Ltd (a Johnson & Johnson Company) · emc · SmPC §5.2 Pharmacokinetic properties · Version 11Document updated
Sources checked